Post transplant lymphoproliferative disorders (PTLD) are life-threatening complications of hematopoietic SCT as well as organ transplantation, caused by EBV-driven B-cell growth combined with defective T-cell immunity.
1 PTLD mostly occurs during the first 6 months after hematopoietic SCT and originates from the donor cell compartment; however, PTLD pathogenesis is not completely understood.
2 PTLD appears to be at increasing risk after umbilical cord blood unrelated transplants (UCBT), mainly due to the graft immunoincompetence and slow engraftment, as well as to the use of antithymocyte globuline (ATG) in the preparative regimens. 3 Double UCBT is an emerging procedure aiming to increase the number of infused cells, widening UCBT application to the adult population. 4 Here, we describe the characteristics of an EBV-PTLD of the ungrafted donor cell origin, with very early onset after double UCBT, in an adult patient.
A 23-year-old man with severe aplastic anemia, polytransfused and treated with immunosuppressive chemotherapy for 3 years, was transplanted in September 2006, with two unrelated UCB units (UCB-1 and UCB-2), both female, from the National Cord Blood Program, New York, USA. Grafts were five/six HLA-matched (UCB-1 and 2, A-and C-mismatched, respectively) and were sequentially infused, with CD34 þ cell doses of 0.16 Â 10 6 /kg (total 9.7 Â 10 6 ) for UCB-1 and 0.09 Â 10 6 / kg (total 5.2 Â 10 6 ) for UCB-2. Umbilical cord blood-2 was seropositive for CMV (IgG þ /IgMÀ), whereas the EBV serologic status of grafts was not investigated. The patient was seropositive for CMV and EBV (VCA IgG þ /IgMÀ) before transplantation.
Preparative regimen consisted of CY (50 mg/kg once daily i.v. from days À5 to À2; total dose 200 mg/kg) with TBI (200 cGy) and horse ATG administered at 2.5 mg/kg/ day for 4 days (total dose 10 mg/kg). GVHD prophylaxis consisted of CsA and mycophenolate mofetil.
Neutrophil engraftment (ANC40.5 Â 10 9 /l) was recorded on day þ 21, whereas platelet engraftment was delayed. On day þ 40, grade I GVHD was diagnosed, which evolved to grade II by day þ 60. CsA was augmented to 300 mg/kg/day. Coincidently, a sinusitis accompanied by hemicranial migraine, disphagy and mild cervical adenomegaly ensued during prophylactic antibiotic therapy. Lactic dehydrogenase value was 267 U/l (reference 150-380 U/l). By day þ 80, the GVHD was resolved, but sinusitis and nasal congestion persisted, with lactic dehydrogenase of 228 U/l. On day þ 100, video laryngoscopy analysis detected a mass in the postero-lateral wall of the nasopharynx and sinonasal cavity, which was confirmed by computerized tomography. On day þ 120, a monomorphic diffuse large B-cell lymphoma was diagnosed in a biopsy sample based on histopathological and molecular findings, and was treated with one cycle of CHOP plus rituximab followed by three isolated cycles of rituximab, without clinical response. The patient underwent central nervous system involvement with malignant cells, and died 138 days after transplant, while receiving intrathecal chemotherapy and cranial radiotherapy.
Hematopoietic chimerism was studied in sequential samples, by fluorescent STR-PCR, as described. 5 On days þ 30 and þ 43, a complete donor chimerism was detected, with a predominance of UCB-1. UCB-1 consolidation occurred gradually from days þ 60 to þ 120 (Supplementary Table S1 ) (Figures 1d-f) .
Investigation of PTLD mass sample by specific PCRs for Ig gene rearrangements disclosed monoclonality. Microsatellite analysis showed that the tumor had a donor cell origin, at the expense of the non-grafted UCB-2 ( Figure 1g ). At that time, BM exhibited a predominance of UCB-1 pattern, with no evidence, either morphological or molecular, of tumor infiltration.
The EBV was detected in the tumor mass by EBER-ISH 6 (in situ hybridization for EBV-encoded RNAs), and was shown to express the LMP1 oncoprotein, as well as the lytic transactivator Zebra (Figure 2) . A retrospective PCR study detected EBV DNA in mononuclear cells (MNCs) as early as day þ 43, coincident with the onset of clinical symptoms. Viral load (cell-associated EBV) was quantified with a Taqman real-time PCR 7 (low sensitivity threshold 10 viral copies/10 5 MNC). Increasing EBV levels were detected from day þ 43 (102 copies/10 5 MNC), days þ 60 (870 copies/10 5 MNC) to þ 120 (3206 copies/10 5 MNC). Recently, Reddiconto et al. 8 described an adult patient with EBV-associated PTLD of donor cell origin following double UCB transplantation. Several differences can be outlined between the two cases. Both PTLDs had origin in donor cells and occurred in the first year post transplantation; however, in our case, PTLD originated from the loser (non-grafted) UCB with a very early onset (days þ 40 to þ 100) compared with a grafted UCB origin and a later onset ( þ 9 months) in Reddiconto's report. Clonality status was also different (polyclonal vs MNCs in our case). Another important difference was that, despite both cases being EBV-associated, in ours, EBV viral load was detectable early after transplantation compared with the absence of detectable viremia, observed in the formerly described PTLD. 8 The observed differences could enlighten pathogenic aspects of PTLD. The underlying disease (severe aplastic anemia) and previous treatment with ATG in our case could have resulted in a more profound specific EBV T-cell immunodeficiency, even in the presence of some degree of graft immunocompetence, shown by the development of GVHD II and the lack of CMV reactivation. This can also explain the differences in both onset time and clonal status exhibited by the compared PTLD cases. Clonality is a variable feature in PTLD, accompanying morphological evolution (early lesions to poly/monomorphic lymphoproliferations) and may be an indicator of potential response to immunosupression withdrawal. 2 In our case, the profound CTL deficit might also have been responsible for the early selection for highly proliferative monoclonal lymphoma cells.
Regarding EBV origin, it is assumed that UCB samples have a low frequency of virus contamination; despite a previous PTLD case in which the presence of EBV DNA was detected in the UCB unit. 9 In our case, the patient was EBV seropositive and EBV DNA was not detected, by any method, in UCB-1 or 2, pointing to a virus host origin. Thus, an early (and perhaps intense) lytic reactivation in the oropharynx mucosa might have resulted in EBV infection of donor B cells. It is likely that, added to the low immunocompetence of UCB grafts and to the ATG-mediated T-lymphocyte depletion, the EBV infected, non-grafted UCB-2 cells could have had additional selective vantage due to an impaired antigen presentation (lack of UCB-2-restricted responses). Cell function and interactions of the loser grafts in double UCBT are not known, and deserve further research as they might represent an additional PTLD risk of these therapeutic protocols. The increase in EBV load seems to precede PTLD diagnosis, making quantitation of viral load a promissory tool for defining the early intervention. In that sense, preemptive rituximab treatment at low EBV loads was shown to successfully control PTLD. 10 Our results confirm the value of sequential EBV load monitoring in predicting PTLD development; however, the contrasting findings of Reddiconto et al., point to the need to better define the value of cell-associated or cell-free (plasma) DNA monitoring in the post-UCBT follow-up. By the other hand, the kinetics of EBV lytic replication in the post transplant setting, as well as its role in PTLD pathogenesis are not well defined and it was proposed that, besides increasing EBV horizontal transfer, lytic cycle proteins can have a pathogenic role in the first stages of PTLD. 2 In summary, we described the first PTLD case after double UCB transplantation with cell origin in the 'loser' graft, in an adult severe aplastic anemia patient conditioned with ATG. We call attention to the need for refining followup parameters, such as the role of specific EBV monitoring, including viral load and lytic cycle markers for PTLD risk prediction after double UCB transplantation.
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